Comparison of the differences between Lucan Sartolizumab and Gosatolizumab (Todavi)

Rukansartuzumab and gosatuzumab (Trodelvy) are both antibody drug conjugates (ADC), which are mainly used to treat different types of cancer, but their targets and indications are significantly different. Rukansartuzumab mainly targets the HER2 receptor and is commonly used in HER2 positive breast cancer patients; while gosatuzumab (< /span>Trodelvy) targets the Trop-2 antigen, and its indications mainly include metastatic urothelial carcinoma and triple-negative breast cancer.

Rukansartuzumab targets the HER2 protein and delivers cytotoxic drugs directly into cancer cells, reducing damage to normal cells and enhancing the therapeutic effect. It is suitable for breast cancer patients with HER2 overexpression or gene amplification, especially to provide a new treatment option after previous treatment failure. In contrast, gosatuzumab combines a linker of a monoclonal antibody against Trop-2 and a cytotoxic linker, which can effectively recognize and kill cancer cells expressing Trop-2 and is suitable for a variety of refractory tumors.

In terms of side effects, common adverse reactions of Sartolizumab include cardiotoxicity, infusion reactions and gastrointestinal symptoms; while Gosatuzumab (Trodelvy) is mainly bone marrow suppression, diarrhea and fatigue, and has a higher risk of neutropenia. Patients should choose drugs based on their doctor's advice and their own condition and tolerance when using them.

In general, although Sartuzumab and Gosatuzumab (Trodelvy) are both antibody-conjugated drugs, they have different treatment mechanisms and side effects for different targets and indications. The choice of which drug should be based on the molecular characteristics of the patient's tumor, previous treatment history, and overall health status should be determined by a professional doctor after a comprehensive evaluation to ensure the best therapeutic effect.

Reference materials:https://www.drugs.com